Joep G J Wijnand1, Martin Teraa1, Hendrik Gremmels2, Femke C C van Rhijn-Brouwer2, Gert J de Borst3, Marianne C Verhaar4. 1. Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, The Netherlands. 2. Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands. 3. Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, The Netherlands. 4. Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands. Electronic address: m.c.verhaar@umcutrecht.nl.
Abstract
BACKGROUND: Critical limb ischemia (CLI) represents the most severe form of peripheral artery disease and has an immense impact on quality of life, morbidity, and mortality. A considerable proportion of CLI patients are ineligible for revascularization, leaving amputation as the only option. Mesenchymal stromal cells (MSCs), because of their vasculoregenerative and immunomodulatory characteristics, have emerged as a potential new treatment. METHODS: The primary objective of this trial is to investigate whether intramuscular administration of allogeneic bone marrow (BM)-derived MSCs is safe and potentially effective. The SAIL (allogeneic mesenchymal Stromal cells for Angiogenesis and neovascularization in no-option Ischemic Limbs) trial is a double-blind, placebo-controlled randomized clinical trial to investigate the effect of allogeneic BM-MSCs in patients with CLI who are not eligible for conventional revascularization. A total of 66 patients will be included and randomized (1:1) to undergo 30 intramuscular injections with either BM-MSCs (5 × 106 MSCs per injection) or placebo in the ischemic lower extremity. Primary outcome, that is, therapy success, a composite outcome consisting of mortality, limb status, clinical status, and changes in pain score, will be assessed at 6 months. All study-related procedures will take place in the University Medical Center Utrecht in The Netherlands. CONCLUSIONS: If our results indicate that intramuscular allogeneic BM-MSC therapy for CLI is safe and potentially effective, this will have important consequences for treatment of patients with CLI. A large multicenter clinical trial with longer follow-up focusing on hard end points should then be initiated to confirm these findings.
RCT Entities:
BACKGROUND:Critical limb ischemia (CLI) represents the most severe form of peripheral artery disease and has an immense impact on quality of life, morbidity, and mortality. A considerable proportion of CLI patients are ineligible for revascularization, leaving amputation as the only option. Mesenchymal stromal cells (MSCs), because of their vasculoregenerative and immunomodulatory characteristics, have emerged as a potential new treatment. METHODS: The primary objective of this trial is to investigate whether intramuscular administration of allogeneic bone marrow (BM)-derived MSCs is safe and potentially effective. The SAIL (allogeneic mesenchymal Stromal cells for Angiogenesis and neovascularization in no-option Ischemic Limbs) trial is a double-blind, placebo-controlled randomized clinical trial to investigate the effect of allogeneic BM-MSCs in patients with CLI who are not eligible for conventional revascularization. A total of 66 patients will be included and randomized (1:1) to undergo 30 intramuscular injections with either BM-MSCs (5 × 106 MSCs per injection) or placebo in the ischemic lower extremity. Primary outcome, that is, therapy success, a composite outcome consisting of mortality, limb status, clinical status, and changes in pain score, will be assessed at 6 months. All study-related procedures will take place in the University Medical Center Utrecht in The Netherlands. CONCLUSIONS: If our results indicate that intramuscular allogeneic BM-MSC therapy for CLI is safe and potentially effective, this will have important consequences for treatment of patients with CLI. A large multicenter clinical trial with longer follow-up focusing on hard end points should then be initiated to confirm these findings.
Authors: S Fadilah Abdul Wahid; Nor Azimah Ismail; Wan Fariza Wan Jamaludin; Nor Asiah Muhamad; Muhammad Khairul Azaham Abdul Hamid; Hanafiah Harunarashid; Nai Ming Lai Journal: Cochrane Database Syst Rev Date: 2018-08-29
Authors: Mark G MacAskill; Jaimy Saif; Alison Condie; Maurits A Jansen; Thomas J MacGillivray; Adriana A S Tavares; Lucija Fleisinger; Helen L Spencer; Marie Besnier; Ernesto Martin; Giovanni Biglino; David E Newby; Patrick W F Hadoke; Joanne C Mountford; Costanza Emanueli; Andrew H Baker Journal: Mol Ther Date: 2018-03-28 Impact factor: 11.454
Authors: Laura V Lozano Navarro; Xueyi Chen; Lady Tatiana Giratá Viviescas; Andrea K Ardila-Roa; Maria L Luna-Gonzalez; Claudia L Sossa; Martha L Arango-Rodríguez Journal: Stem Cell Res Ther Date: 2022-07-26 Impact factor: 8.079
Authors: Rhayra B Dias; João A M Guimarães; Marco B Cury; Leonardo R Rocha; Elaine S da Costa; Liebert P Nogueira; Camila Hochman-Mendez; Anneliese Fortuna-Costa; Anna Karoline F Silva; Karin S Cunha; Sergio A L de Souza; Maria Eugênia L Duarte; Rafaela C Sartore; Danielle C Bonfim Journal: Stem Cells Int Date: 2019-11-07 Impact factor: 5.443